ADDITIONAL INFORMATION 21 Purpose Maximum amount Period of validity Global maximum Use of the Residual maximum amount in euros delegations amount in euros Delegation of powers given to the Board of Capital increase: 18 months i.e. until — Directors in order to issue ordinary shares 85% of the share October 12, 2019 giving right, as the case may be, to ordinary capital at the shares or the allocation of debt securities (of date of the 2018 the company or a company of the group), and/ Shareholder’s or securities giving a right to ordinary shares Meeting i.e. (of the company or a company of the group), €514,977.24 without preferential subscription rights in Debt instruments favour of categories of persons satisfying giving access to determined characteristics(4)in accordance with equity securities: the provisions of articles L.225-129-2, L.225- €50,000,000 138 and L.228-92 of the Commercial Code (21 resolst ution). Authorization given to the Board of Directors 5% of the share 38 months i.e. until — with a view to the granting of options for the capital at the June 12, 2021 subscription and/or purchase of shares to date of the 2018 members of the salaried work force (and/or Shareholder’s Capital increase: certain corporate officers) in accordance with Meeting i.e. 100%of the share the provisions of articles L.225-177 to L.225- €30,292.78 capital at the 185 of the Commercial Code (22 resolution).nd 1,211,711 options date of the 2018 Capital increase: Shareholder’s €605,855.58 Authorization given to the Board of Directors 10% of the share 38 months i.e. until Meeting i.e. — Debt instruments with a view to allocating free of charges shares capital at the June 12, 2021 €605,855.58 giving access to to members of the salaried work force and/or date of the 2018 equity securities: certain corporate officers in accordance with Shareholder’s Debt instruments €50,000,000 the provisions of articles L.225-197-1 and Meeting i.e. giving access to L.225-197-2 of the Commercial Code (23rd €60,585.56 equity securities: resolution). 2,423,422free shares €50,000,000 Delegation to be given to the Board of Directors 5% of the share 18 months i.e. until — with a view to issuing share subscription capital at the October 12, 2019 warrants (bons de souscription d’actions (BSA)), date of the 2018 subscription warrants and/or purchase Shareholder’s warrants for new shares and/or existing Meeting i.e. shares (bons de souscription et/ou d’acquisition €30,292.78 d’actions nouvelles et/ou existantes (BSAANE)) 1,211,711share and/or subscription warrants and/or purchase warrants warrants for new shares and/or existing redeemable shares (bons de souscription et/ou d’acquisitiond’actions nouvelleset/ou existantes remboursables (BSAAR)) with preferential subscription rights waived in favor of categories of persons(5) (6)in accordance with the provisions of articles L.225-129-2, L.225-138 and L.228- 91 of the Commercial Code (24 resth olution). (1) The issue price should at least be equal to the minimum required by the legal and regulatory provisions applicable at the time when the Board of Directors shall implement the delegation (for reference, to date the weighted average of the listed prices of the share on the regulated Euronext Paris market for the three trading sessions preceding the determination of the subscription price for the increase in capital decreased by a maximum discount of 5%) (2) The issue price of the ordinary shares shall at least be equal, at the choice of the Board of Directors (i) either to the weighted average of the company share price on the Euronext Paris regulated market on the date preceding the determination of the issue price, which may be decreased by a maximum discount of 15%, (ii) or the average of 5 consecutive listed prices of the company share on the Euronext Paris regulated market chosen amongst the thirty trading sessions preceding the determination of the issue price, which may be decreased by a maximum discount of 15%. (3) The issue price should at least be equal to the average weighted by the volumes (in the central order book and not including blocks and off market) of the price of the Company’s shares on the Euronext Paris regulated market for the last 3 trading sessions preceding the determination of the issue price, such average subject to amendment as the case may be in order to take into account the differences in the entitlement to dividends date and may be decreased as the case may be by a maximum discount of 15%. (4) The present delegation shall be made in favor of the following categories of persons: (i)i ndividual or legal entities (including companies), investment companies, trusts, investment funds, or other investment vehicles of any form whatsoever, whether French or foreign generally investing in the pharmaceutical, bio-technological, ophthalmological, neurodegenerative diseases or medical technologies sectors; and/or (ii) companies, institutions or entities of any form whatsoever, whether French or foreign conducting a significant part of their business in those sectors; and/or. (iii) financial service providers, being French or foreign with an equivalent status, capable of guaranteeing that an increase in capital will be successfully placed with the persons referred to in (i) and (ii) hereabove and, in this context, subscribing to the issued securities. (5) The issue price of the warrant shall equal to at least 8% of the market value of an ordinary share on the date of attribution. (6) The price for the subscription and/or purchase of the shares to which the warrants shall give right shall at least be equal to the weighted average of the closing prices of the Company’s shares for the last 20 trading sessions preceding the date of the decision to issue warrants, deducted by any issue price of the warrant. 222– GENSIGHT BIOLOGICS – 2017 Registration Document